Paclitaxel (TAXOL®), a novel diterpene plant product isolated from the western yew Taxus brevifolia, is an active agent in the treatment of lung cancer. In two studies, the drug produced 21% and 24% objective response rates among patients with non-small cell lung cancer. A response rate of 34% was reported in a single trial involving patients with extensive-stage small cell lung cancer. Additional trials are needed to evaluate single-agent paclitaxel in the treatment of small cell lung cancer. Studies also are planned to measure the effect of paclitaxel as a radiosensitizer and in combination regimens with other active agents for the treatment of lung cancer.
|Original language||English (US)|
|Number of pages||4|
|Journal||Seminars in oncology|
|Issue number||4 SUPPL. 3|
|State||Published - Aug 23 1993|
ASJC Scopus subject areas